Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

Professor of Medicine in Neurology, University of Ottawa; Director, Multiple Sclerosis Research Unit, Ottawa Hospital; Senior Scientist, Ottawa Hospital Research Institute

Articles by Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

Misdiagnosis of Multiple Sclerosis

ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

December 25th 2020

Use of MRI in Diagnosing Multiple Sclerosis

ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

December 23rd 2020

2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis

ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

December 16th 2020

Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

CLARITY Extension Trial: Disability Improvement With Cladribine

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

OLKIOS: Looking at Ofatumumab’s Continued Efficacy

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Mark Freedman, MD: An Update on Stem Cell Research in MS

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

May 22nd 2020

The director of the multiple sclerosis research unit at Ottawa Hospital discussed stem cell therapies being explored in multiple sclerosis, and which patients may be eligible for these treatments.

Mark Freedman, MD: Early Intervention With Interferon Beta-1b for Patients Presenting With CIS

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

March 28th 2019

The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the results of BENEFIT 15 that support early intervention of interferon beta-1b treatment at or shortly after CIS.

Mark Freedman, MD: Precision Medicine in Multiple Sclerosis

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

March 24th 2019

The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the need for clinicians to select the right patient for the right treatment in the MS clinic.

Mark Freedman, MD: Long-Term Efficacy and Safety Studies in MS

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

March 9th 2019

The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the importance of long-term efficacy studies.

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

Articles by Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

Misdiagnosis of Multiple Sclerosis

Use of MRI in Diagnosing Multiple Sclerosis

2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis

Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

CLARITY Extension Trial: Disability Improvement With Cladribine

Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

OLKIOS: Looking at Ofatumumab’s Continued Efficacy

Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

Mark Freedman, MD: An Update on Stem Cell Research in MS

Mark Freedman, MD: Early Intervention With Interferon Beta-1b for Patients Presenting With CIS

Mark Freedman, MD: Precision Medicine in Multiple Sclerosis

Mark Freedman, MD: Long-Term Efficacy and Safety Studies in MS

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease

B-Cell Modulator Obexelimab Shows Pronounced Relapse Reduction in Phase 2 MoonStone Trial

Apomorphine Sublingual Film Displays Efficacy in Elderly Patients with Parkinson Disease

Independent Adjudication Committee Helps Facilitate Accurate Enrollment of Phase 2/3 ARISE Trial of Nipocalimab

Expanding Patient Expectations When Managing Generalized Myasthenia Gravis: A Treating Physician’s Experience with IMAAVY™ (nipocalimab-aahu)